WARPTECHNEWS · LAB

Home AI Business Tech Archive

Storia: Novo Dives On A Key Miss As Its Battle With Lilly Heats Up — Warptech Lab News

Storia in 7 fonti

Novo Dives On A Key Miss As Its Battle With Lilly Heats Up

Novo Nordisk stock plummeted Tuesday after the obesity kingpin unexpectedly released its second-quarter earnings a day early.

Raccontata da

independent.co.uk

biopharmadive.com

economictimes.indiatimes.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

investors.comStai leggendo1 g fa

Novo Dives On A Key Miss As Its Battle With Lilly Heats Up

Novo Nordisk stock plummeted Tuesday after the obesity kingpin unexpectedly released its second-quarter earnings a day early.

Timeline cronologica

lunedì 3 agosto 2026·independent.co.uk
GLP-1 battle heats up again as Novo claws its way back into race with Lilly
The two pharmaceutical giants are locked in a fierce battle for dominance in the burgeoning obesity drug market
martedì 4 agosto 2026·endpoints.news
Novo vs. Lilly: Q2's cardiometabolic grudge match
Novo Nordisk and Eli Lilly are reporting Q2 earnings this week, as Novo's Wegovy pill outsells Lilly's Foundayo and a dealmaking divide develops between the obesity rivals.

biopharmadive.com

1 g fa

Lilly climbs, Novo falls as obesity drug battle intensifies

A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.

Leggi questa versione → originale

endpoints.news1 g fa

Novo vs. Lilly: Q2's cardiometabolic grudge match

Novo Nordisk and Eli Lilly are reporting Q2 earnings this week, as Novo's Wegovy pill outsells Lilly's Foundayo and a dealmaking divide develops between the obesity rivals.

Leggi questa versione → originale

benzinga.com1 g fa

Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks - Novo Nordisk

Novo Nordisk raises 2026 guidance as Wegovy pill tops 5 million U.S. prescriptions, but stock falls despite higher GLP-1 sales expectations.

Leggi questa versione → originale

independent.co.uk2 g fa

GLP-1 battle heats up again as Novo claws its way back into race with Lilly

The two pharmaceutical giants are locked in a fierce battle for dominance in the burgeoning obesity drug market

Leggi questa versione → originale

Novo Nordisk's raised forecast fails to change the debate over its obesity business

Novo Nordisk hiked guidance to flat on Wegovy (5M+ prescriptions) but Eli Lilly's share gains and weak CagriSema results disappointed. Stock down 70% signals pipeline weakness and execution risk as obesity pioneer loses leadership to faster competitors.

Leggi questa versione → originale

martedì 4 agosto 2026·

cnbc.com

Novo Nordisk shares slide after guidance disappoints investors

Novo Nordisk raised its financial outlook as it tries to catch up with rival Eli Lilly in the booming GLP-1 market.

martedì 4 agosto 2026·

investors.com

Novo Dives On A Key Miss As Its Battle With Lilly Heats Up

Novo Nordisk stock plummeted Tuesday after the obesity kingpin unexpectedly released its second-quarter earnings a day early.

martedì 4 agosto 2026·

benzinga.com

Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks - Novo Nordisk

Novo Nordisk raises 2026 guidance as Wegovy pill tops 5 million U.S. prescriptions, but stock falls despite higher GLP-1 sales expectations.

mercoledì 5 agosto 2026·

biopharmadive.com

Lilly climbs, Novo falls as obesity drug battle intensifies

A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.

mercoledì 5 agosto 2026·

cnbc.com

Novo Nordisk's raised forecast fails to change the debate over its obesity business

Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.

mercoledì 5 agosto 2026·

economictimes.indiatimes.com

Novo CEO says setbacks demand faster research, acquisitions as investors fret over pipeline

Novo Nordisk CEO Mike Doustdar said the company will speed up research and pursue smaller acquisitions to strengthen its drug pipeline after recent trial setbacks. The company…

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com